文献速递前列腺癌

术中前列腺压迫辅助高强度聚焦超声局灶治疗局限性前列腺癌:7年经验的多中心前瞻性研究

Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-11-23

多中心前瞻性研究纳入240例局限性前列腺癌患者,采用术中前列腺压迫辅助高强度聚焦超声局灶治疗,中位随访48个月。低、中、高危组单次治疗后生化无病生存率分别为93.7%、88.5%、84.8%,病理无病生存率分别为92.2%、91.6%、86.6%。作者认为该疗法可改善中期肿瘤学结局且无功能恶化风险。

要点

  • 低危组单次治疗后生化无病生存率93.7%,中危组88.5%,高危组84.8%。
  • 低危组病理无病生存率92.2%,中危组91.6%,高危组86.6%。
  • 治疗后1个月排尿与性功能下降,3或6个月恢复至术前水平。

核心结论

  • 作者认为术中前列腺压迫辅助高强度聚焦超声局灶治疗可改善中期肿瘤学结局,且无功能恶化风险。

研究设计与样本

  • 多中心前瞻性研究,纳入240例局限性前列腺癌患者,中位年龄69岁,中位前列腺特异抗原6.42 ng/mL。
  • 纳入标准为前列腺特异抗原≤20 ng/mL且临床显著前列腺癌位于前列腺左半或右半、上半或下半。
  • 临床显著前列腺癌经磁共振成像-经直肠超声融合图像引导靶向穿刺与12针系统穿刺检出。
  • 对磁共振成像可见病灶行术中前列腺压迫辅助高强度聚焦超声局灶治疗。
  • 按D'Amico危险分类分为低危组51例、中危组107例、高危组82例。

主要发现

  • 低、中、高危组单次治疗后生化无病生存率分别为93.7%、88.5%、84.8%。
  • 低、中、高危组单次治疗后病理无病生存率分别为92.2%、91.6%、86.6%。
  • 低、中、高危组免根治性或系统性治疗生存率分别为96.1%、94.4%、95.1%。
  • 中位随访48个月(范围24-84个月)。
  • 治疗后1个月排尿与性功能下降,治疗后3或6个月恢复至术前水平。

关键数值与推荐

  • 生化失败采用Phoenix ASTRO定义。
  • 病理失败定义为生化失败时穿刺活检检出临床显著前列腺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate clinical outcomes of focal therapy using high-intensity focused ultrasound (HIFU) with intraoperative prostate compression for patients with localized prostate cancer (PC). METHODS: Patients were included if they had prostate specific antigen levels of ≤20 ng/mL and clinically significant PC (CSPC) within the left or right half, or upper or lower half of the prostate. CSPC was detected using magnetic resonance imaging-transrectal ultrasound fusion image-guided target biopsy and a 12-core systematic biopsy. Focal therapy using HIFU with intraoperative prostate compression was administered to lesions visible on the magnetic resonance imaging. Biochemical failure was defined by the Phoenix ASTRO definition. Pathological failure was defined as having CSPC in the biopsy at the time of biochemical failure. RESULTS: The patients (n = 240; median age, 69 years old; median prostate specific antigen level, 6.42 ng/mL) were divided according to the D'Amico risk classification into: 'low' (n = 51), 'intermediate' (n = 107), and 'high' (n = 82) groups. The biochemical and the pathological disease-free survival rates after a single treatment for the low-, intermediate-, and high-risk groups were 93.7% and 92.2%, 88.5% and 91.6%, and 84.8% and 86.6%, respectively. The radical or systematic treatment-free survival rates were 96.1%, 94.4%, and 95.1%, respectively. Median follow-up period was 48 months (range 24-84). The urinary and sexual function at 1 month post-treatment had deteriorated but returned to preoperative levels at 3 or 6 months after treatment. CONCLUSIONS: Focal therapy using HIFU with intraoperative prostate compression would improve medium-term oncological outcomes without the risk of functional deterioration.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shoji S, Naruse J, Ohno S, et al. Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience. Prostate Cancer Prostatic Dis. 2024. PMID: 39580599. doi:10.1038/s41391-024-00921-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。